- Home
- CLDI vs BTAI Comparison
CLDI vs BTAI Comparison
Compare CLDI & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- BTAI
- Stock Information
- Founded
- CLDI 2014
- BTAI 2017
- Country
- CLDI United States
- BTAI United States
- Employees
- CLDI N/A
- BTAI N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- BTAI Health Care
- Exchange
- CLDI Nasdaq
- BTAI Nasdaq
- Market Cap
- CLDI 10.2M
- BTAI 8.3M
- IPO Year
- CLDI N/A
- BTAI 2018
- Fundamental
- Price
- CLDI $0.71
- BTAI $1.92
- Analyst Decision
- CLDI
- BTAI Buy
- Analyst Count
- CLDI 0
- BTAI 5
- Target Price
- CLDI N/A
- BTAI $34.60
- AVG Volume (30 Days)
- CLDI 41.3M
- BTAI 291.4K
- Earning Date
- CLDI 08-12-2025
- BTAI 08-05-2025
- Dividend Yield
- CLDI N/A
- BTAI N/A
- EPS Growth
- CLDI N/A
- BTAI N/A
- EPS
- CLDI N/A
- BTAI N/A
- Revenue
- CLDI N/A
- BTAI $1,852,000.00
- Revenue This Year
- CLDI N/A
- BTAI $5.03
- Revenue Next Year
- CLDI N/A
- BTAI $291.01
- P/E Ratio
- CLDI N/A
- BTAI N/A
- Revenue Growth
- CLDI N/A
- BTAI 5.47
- 52 Week Low
- CLDI $0.20
- BTAI $1.17
- 52 Week High
- CLDI $3.89
- BTAI $21.92
- Technical
- Relative Strength Index (RSI)
- CLDI 65.65
- BTAI 57.21
- Support Level
- CLDI $0.23
- BTAI $1.81
- Resistance Level
- CLDI $1.60
- BTAI $2.15
- Average True Range (ATR)
- CLDI 0.15
- BTAI 0.18
- MACD
- CLDI 0.07
- BTAI 0.01
- Stochastic Oscillator
- CLDI 36.55
- BTAI 60.40
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.